Literature DB >> 12538697

Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments.

Géza Ambrus1, Péter Gál, Mayumi Kojima, Katalin Szilágyi, Júlia Balczer, József Antal, László Gráf, Andreas Laich, Beryl E Moffatt, Wilhelm Schwaeble, Robert B Sim, Péter Závodszky.   

Abstract

Mannan-binding lectin-associated serine protease (SP) (MASP)-1 and MASP-2 are modular SP and form complexes with mannan-binding lectin, the recognition molecule of the lectin pathway of the complement system. To characterize the enzymatic properties of these proteases we expressed their catalytic region, the C-terminal three domains, in Escherichia coli. Both enzymes autoactivated and cleaved synthetic oligopeptide substrates. In a competing oligopeptide substrate library assay, MASP-1 showed extreme Arg selectivity, whereas MASP-2 exhibited a less restricted, trypsin-like specificity. The enzymatic assays with complement components showed that cleavage of intact C3 by MASP-1 and MASP-2 was detectable, but was only approximately 0.1% of the previously reported efficiency of C3bBb, the alternative pathway C3-convertase. Both enzymes cleaved C3i 10- to 20-fold faster, but still at only approximately 1% of the efficiency of MASP-2 cleavage of C2. We believe that C3 is not the natural substrate of either enzyme. MASP-2 cleaved C2 and C4 at high rates. To determine the role of the individual domains in the catalytic region of MASP-2, the second complement control protein module together with the SP module and the SP module were also expressed and characterized. We demonstrated that the SP domain alone can autoactivate and cleave C2 as efficiently as the entire catalytic region, while the second complement control protein module is necessary for efficient C4 cleavage. This behavior strongly resembles C1s. Each MASP-1 and MASP-2 fragment reacted with C1-inhibitor, which completely blocked the enzymatic action of the enzymes. Nevertheless, relative rates of reaction with alpha-2-macroglobulin and C1-inhibitor suggest that alpha-2-macroglobulin may be a significant physiological inhibitor of MASP-1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538697     DOI: 10.4049/jimmunol.170.3.1374

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes.

Authors:  Asli Sirmaci; Tom Walsh; Hatice Akay; Michail Spiliopoulos; Yıldırım Bayezit Sakalar; Aylin Hasanefendioğlu-Bayrak; Duygu Duman; Amjad Farooq; Mary-Claire King; Mustafa Tekin
Journal:  Am J Hum Genet       Date:  2010-10-28       Impact factor: 11.025

2.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

Review 3.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

4.  Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.

Authors:  K S Brown; M J Keogh; N Tagiuri; M J Grainge; J S Presanis; S D Ryder; W L Irving; J K Ball; R B Sim; T P Hickling
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Structural basis for activation of the complement system by component C4 cleavage.

Authors:  Rune T Kidmose; Nick S Laursen; József Dobó; Troels R Kjaer; Sofia Sirotkina; Laure Yatime; Lars Sottrup-Jensen; Steffen Thiel; Péter Gál; Gregers R Andersen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

6.  Quantitative characterization of the activation steps of mannan-binding lectin (MBL)-associated serine proteases (MASPs) points to the central role of MASP-1 in the initiation of the complement lectin pathway.

Authors:  Márton Megyeri; Veronika Harmat; Balázs Major; Ádám Végh; Júlia Balczer; Dávid Héja; Katalin Szilágyi; Dániel Datz; Gábor Pál; Péter Závodszky; Péter Gál; József Dobó
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

7.  Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation.

Authors:  Ulrich auf dem Keller; Anna Prudova; Ulrich Eckhard; Barbara Fingleton; Christopher M Overall
Journal:  Sci Signal       Date:  2013-01-15       Impact factor: 8.192

8.  Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.

Authors:  Krishana C Gulla; Kshitij Gupta; Anders Krarup; Peter Gal; Wilhelm J Schwaeble; Robert B Sim; C David O'Connor; Krishnan Hajela
Journal:  Immunology       Date:  2009-12-02       Impact factor: 7.397

9.  Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis.

Authors:  Michaela Windbichler; Bernd Echtenacher; Thomas Hehlgans; Jens C Jensenius; Wilhelm Schwaeble; Daniela N Männel
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

10.  Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D.

Authors:  Minoru Takahashi; Yumi Ishida; Daisuke Iwaki; Kazuko Kanno; Toshiyuki Suzuki; Yuichi Endo; Yoshimi Homma; Teizo Fujita
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.